A previous trial involving patients with metastatic prostate cancer that was resistant to androgen pathway modulation (formerly referred to as castration-resistant) showed that adding talazoparib ...
Secret Life of Mom on MSN
Easier way to treat prostate cancer could become new 'standard of care,' doctors say
Every year, hundreds of thousands of men receive a prostate cancer diagnosis and immediately face a decision that medical ...
Abstract: Micro-ultrasound is an emerging imaging tool that complements MRI in detecting prostate cancer by offering highresolution imaging at lower cost. However, reliable annotations for ...
An ultrasound-based treatment for prostate cancer showed better safety and operative metrics versus robotic radical prostatectomy in an early analysis of a first-ever randomized trial. After 6 months ...
A NURSE-LED bladder management approach improved bladder volume reproducibility and reduced repeat imaging in prostate hypofractionated radiotherapy. In a retrospective analysis, investigators ...
OPTIMUM demonstrated noninferiority for grade group ≥2 detection (46% micro-ultrasound vs 43% MRI/US fusion; difference 3.52%; 95% CI −3.95% to 10.92%; P<.001). Comparable detection of grade group ≥3 ...
Treatment interruption guided by on-treatment prostate-specific membrane antigen (PSMA) PET/CT imaging in metastatic hormone-sensitive prostate cancer (mHSPC). This is an ASCO Meeting Abstract from ...
In a population-based cohort study, a single prostate-specific antigen (PSA) measurement in men aged 45-70 years effectively identified individuals with low risk for cancer. Men with PSA levels < 1.00 ...
Prostatomegaly is a common condition in adult, intact dogs. Abdominal ultrasonography is currently considered the method of choice for assessing the prostate size using volume-based formulas. However, ...
The European Society for Medical Oncology has updated its clinical practice guidelines for the management of localised prostate cancer and biochemical recurrence, refining diagnostic pathways and ...
For prostate cancer patients with low-volume tumors and metastasis, the median overall survival was 37.13 months. Prostate cancer patients with metastatic disease and low-volume primary tumors appear ...
High-intensity focused ultrasound (HIFU) is a noninvasive way to destroy tissue or stop it from working. It was approved by the U.S. Food and Drug Administration for prostate ablation in 2015, but the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results